Article Abstract

Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4–5 chronic kidney disease

Authors: Kalyan Ram Bhamidimarri


The prevalence of Hepatitis C (HCV) in patients with advanced renal disease and dialysis is higher than that of general population with rates around 5–10% in Europe and USA (1,2). The prevalence of HCV also correlates with the duration or number of years on hemodialysis (3). Furthermore, HCV-infected patients receiving maintenance dialysis have an increased mortality when compared to the uninfected population (4). HCV is not only associated with the development and progression of chronic kidney disease in non-dialysis patients but also with progressive liver disease in dialysis patients (5).


  • There are currently no refbacks.

Article Options

Download Citation